118 related articles for article (PubMed ID: 37634247)
1. Preventive Effects of Nicorandil and Atorvastatin in Contrastinduced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Artery Angiography: A Double Blind, Randomized, Controlled Clinical Trial.
Mohammadi Kebar S; Atighi E; Hosseninia S; Babapour B
Iran J Kidney Dis; 2023 Jul; 17(4):205-214. PubMed ID: 37634247
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
Fan Z; Li Y; Ji H; Jian X
Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
6. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
[TBL] [Abstract][Full Text] [Related]
7. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
[TBL] [Abstract][Full Text] [Related]
8. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
9. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
[TBL] [Abstract][Full Text] [Related]
11. Preventive Effect of Atorvastatin (80 mg) on Contrast-Induced Nephropathy After Angiography in High-Risk Patients: Double-Blind Randomized Clinical Trial.
Khosravi A; Dolatkhah M; Hashemi HS; Rostami Z
Nephrourol Mon; 2016 May; 8(3):e29574. PubMed ID: 27570749
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
13. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
Zhan B; Huang X; Jiang L; Bao H; Cheng X
Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
[TBL] [Abstract][Full Text] [Related]
14. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
15. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.
Zhang X; Yang S; Zhang P; Fu N
Coron Artery Dis; 2020 May; 31(3):284-288. PubMed ID: 31658134
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Contrast-induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Elective Coronary Angioplasty or Angiography with Sodium Potassium Citrate Solution, a Double Blind Randomized Clinical Trial.
Ghorbani A; Yazdankhah S; Adel MH; Tabesh H; Sattari AR; Sattari SA; Heybar H; Madjidi S
Iran J Kidney Dis; 2019 May; 13(3):182-190. PubMed ID: 31209191
[TBL] [Abstract][Full Text] [Related]
18. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin and prevention of contrast induced nephropathy following coronary angiography.
Bidram P; Roghani F; Sanei H; Hedayati Z; Golabchi A; Mousavi M; Hajiannejad A; Pourheidar B; Badalabadi MM; Gharaati M; Akhbari M; Salesi A
J Res Med Sci; 2015 Jan; 20(1):1-6. PubMed ID: 25767514
[TBL] [Abstract][Full Text] [Related]
20. Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization.
Zeng Z; Fu X; Zhang X; Fu N
Int Urol Nephrol; 2019 Nov; 51(11):1999-2004. PubMed ID: 31385178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
